Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
LCTX Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals. While there are positive aspects such as increased revenue expectations from OpRegen, potential partnerships, and optimism in the cell therapy market, there are concerns about rising expenses and net loss, as well as lack of specific data insights from ongoing studies. The Q&A reveals cautious optimism but also highlights uncertainties, particularly in data availability and competitive positioning. These factors balance each other out, suggesting a neutral impact on stock price.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call indicates strong revenue growth, improved margins, and a significant reduction in net loss, showcasing operational efficiencies. The company's strategic initiatives in cell therapy, particularly the OpRegen program, along with optimistic market trends, signal positive future prospects. Despite the absence of shareholder return discussions, the financial health and strategic outlook suggest a positive sentiment. The lack of negative sentiment in the Q&A further supports a positive rating, with expectations of a stock price increase in the 2% to 8% range.
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals mixed signals. Positives include potential $37 million milestone payment from OpRegen, new manufacturing processes, and strategic partnerships. However, the significant net loss, unclear management responses, and reliance on future funding present risks. The Q&A highlights potential expansion with the CIRM grant and partnership strategies, but uncertainties remain. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript
Neutral9-13
LCTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
